Skip to main content

Peer Review reports

From: Axitinib and crizotinib combination therapy inhibits bone loss in a mouse model of castration resistant prostate cancer

Original Submission
11 Jul 2014 Submitted Original manuscript
14 Jul 2014 Author responded Author comments - Anand Giddabasappa
Resubmission - Version 2
14 Jul 2014 Submitted Manuscript version 2
9 Sep 2014 Author responded Author comments - Anand Giddabasappa
13 Aug 2014 Reviewed Reviewer Report - Colin Rae
28 Aug 2014 Reviewed Reviewer Report - Joanne Edwards
Resubmission - Version 3
9 Sep 2014 Submitted Manuscript version 3
17 Sep 2014 Author responded Author comments - Anand Giddabasappa
Resubmission - Version 4
17 Sep 2014 Submitted Manuscript version 4
22 Sep 2014 Author responded Author comments - Anand Giddabasappa
Resubmission - Version 5
22 Sep 2014 Submitted Manuscript version 5
Publishing
23 Sep 2014 Editorially accepted
2 Oct 2014 Article published 10.1186/1471-2407-14-742

You can find further information about peer review here.

Back to article page